Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 3/20 | 0.42 |
| ▸ | APEX1 | P27695 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828703 | 0.76 | AOC3 (0.50) | AOC3CCNE2CCNE1CDK2MAPT | |
| SCHEMBL521779 | 0.73 | MAPT (0.58) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL521780 | 0.73 | MAPT (0.58) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL17053665 | 0.72 | MAPT (0.56) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL9768301 | 0.71 | MAPT (0.68) | AOC3MAPTTDP1ADRB2KDM4E | |
| SCHEMBL5828700 | 0.71 | ADRA1A (0.50) | AOC3MAPTTDP1ADRB2KDM4E | |
| SCHEMBL8690259 | 0.70 | AKR1C3 (0.51) | MAPTTDP1MEN1KMT2ATSHR | |
| SCHEMBL11155392 | 0.70 | ADRB2 (0.50) | AOC3TDP1ADRB2ADRB1CYP3A4 | |
| SCHEMBL6479388 | 0.70 | AOC3 (0.74) | AOC3MAPTALDH1A1LMNAPOLB | |
| SCHEMBL25100809 | 0.69 | TDP1 (0.53) | MAPTTDP1ADRB2KDM4EADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109330-B2 | Purine inhibitors of cyclin dependent kinase 2 and IκB-α | CV THERAPEUTICS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | AOC3 3587/4885CCNE2 65/4885CCNE1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.